Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 35,632 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 35,632 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $0.63, for a total value of $22,448.16. Following the completion of the sale, the director owned 2,659,280 shares of the company’s stock, valued at $1,675,346.40. The trade was a 1.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Luke Evnin also recently made the following trade(s):

• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total value of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total value of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.62 on Tuesday. Werewolf Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $2.38. The firm has a market capitalization of $30.15 million, a P/E ratio of -0.38 and a beta of 0.74. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The business has a fifty day simple moving average of $1.06 and a two-hundred day simple moving average of $1.29.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after buying an additional 23,852 shares during the period. Nuveen LLC bought a new stake in Werewolf Therapeutics during the first quarter valued at about $71,000. MPM Asset Management LLC lifted its position in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares in the last quarter. MPM Bioimpact LLC boosted its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after acquiring an additional 20,799 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics during the first quarter worth about $79,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. HC Wainwright dropped their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Bank of America decreased their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Finally, Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.